source
- RevMed's Rasonque shows weaker response in common KRAS pancreatic cancer mutation, shares fall over 6%New data from Revolution Medicines indicates that its KRAS inhibitor Rasonque had a reduced response rate in patients whose pancreatic tumors carry the most common KRAS mutation. The subgroup resp…
- Proposed Census Overhaul Could Undermine Public Health Data, Experts WarnFederal officials are proposing three major revisions to the U.S. Census. The plan would drop questions on race, ethnicity and sexual orientation and would count only U.S. citizens, leaving out non…